FULCRUM THERAPEUTICS, INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $80.0M | $2.8M | $6.3M | $19.2M | $8.8M |
| Cost of Revenue | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| Operating Expenses | ||||||
| Research & Development | $56.1M | $63.4M | $71.8M | $76.8M | $69.7M | $59.0M |
| SG&A Expense | $28.7M | $36.4M | $41.7M | $41.7M | $30.5M | $21.4M |
| Operating Income | $-84.8M | $-21.9M | $-110.7M | $-112.6M | $-81.1M | $-71.6M |
| Operating Margin | — | -27.4% | -3,945.2% | -1,774.9% | -423.0% | -811.6% |
| Interest Expense | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — |
| Income Tax Expense | $0 | $0 | — | — | — | — |
| Net Income | $-74.9M | $-9.7M | $-97.3M | $-109.9M | $-80.8M | $-70.8M |
| Net Margin | — | -12.2% | -3,470.1% | -1,732.4% | -421.9% | -802.7% |
| EPS (Basic) | $-1.18 | $-0.16 | $-1.59 | $-2.44 | $-2.29 | $-2.79 |
| EPS (Diluted) | $-1.18 | $-0.16 | $-1.59 | $-2.44 | $-2.29 | $-2.79 |
| Shares Outstanding (Basic) | 63.4K | 62.0K | 61.3K | 45.0K | 35.4K | 25.4K |
| Shares Outstanding (Diluted) | 63.4K | 62.0K | 61.3K | 45.0K | 35.4K | 25.4K |
| Dividends Per Share | — | — | — | — | — | — |